Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown
 

Adenocarcinoma Clinical Trials

A listing of Adenocarcinoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (896) clinical trials

Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer

PRIMARY OBJECTIVES: I. Establish a 6 month observation period for stage IV non-small cell lung cancer patients (NSCLC) (n=400), using the statewide research network, documenting usual care (UC) practices, survival and quality of life. II. Following the 6 month observation period, conduct a 3 year clinical trial in stage IV ...

Phase N/A

Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer

This study will evaluate the safety and disease control rate of the combination of pembrolizumab plus low-dose interleukin-2 in patients who have either advanced melanoma or renal cell cancer.

Phase

Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer

A total of up to 58 subjects will be enrolled on both phases. Phase Ib: 6-12 subjects; enrolled into either Cohort 1 or 2. Phase II: 46 subjects; enrolled into either Cohort 1 or 2. Cohort 1 (36 subjects): received 0-1 prior therapy and no prior anti-PD-1/PD-L1/CTLA4. Cohort 2 (16 ...

Phase

Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma

Given the superior outcomes with FOLFIRINOX and the potential for improved local response with SBRT, the investigators propose to evaluate the efficacy of pre-operative modified FOLFIRINOX followed by SBRT in patients with borderline resectable pancreatic adenocarcinoma. The investigators hypothesize that pre-operative modified FOLFIRINOX followed by SBRT will improve the rate ...

Phase

A Phase II Trial of the DNA Methyl Transferase Inhibitor Guadecitabine (SGI-110) in Children and Adults With Wild Type GIST Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer

Background Loss of activity of the Krebs cycle components succinate dehydrogenase (SDH) complex or fumarate hydratase (FH), has been identified as a mechanism of tumorigenesis in subsets of gastrointestinal stromal tumor (GIST), pheochromocytoma and paraganglioma (PHEO/PGL), and renal cell carcinoma. DNA hypermethylation has been demonstrated in these cancers. Loss of ...

Phase

Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate Gonadotropin-Releasing Hormone Analog and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery

PRIMARY OBJECTIVES: I. To evaluate the effect of neoadjuvant androgen receptor antagonist ARN-509 (apalutamide) with or without abiraterone acetate, GnRH agonist, and prednisone on the feasibility of performing nerve-sparing radical prostatectomy (RP) in men with high-risk prostate cancer (PCa). OUTLINE: Patients are randomized to 1 of 3 treatment arms. ARM ...

Phase

PSMA PET Imaging of Recurrent Prostate Cancer

The purpose of this study is to see if a new diagnostic research agent named 68Ga-HBED-CC-PSMA can show prostate cancer on a PET/CT scan that cannot be seen on other standard imaging even when the PSA levels are very low.

Phase

Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery

This is a single-center prospective clinical trial to evaluate non-inferiority of indocyanine green guided sentinel lymph node biopsy compared with the gold standard Technecium99 guided sentinel lymph node biopsy in patients with cancers and subjected to surgery. The diagnostic performance and the tolerance of indocyanine green (ICG) to the radio-isotope ...

Phase

Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery

PRIMARY OBJECTIVES: I. To determine the safe dose of olaparib with ramucirumab, but not to exceed olaparib dose of 300 mg twice daily (tablet formulation). (Phase I) II. To determine the efficacy of olaparib plus ramucirumab as measured by the objective response rates (ORR) stratified by BROCA-HR biomarker status. (Phase ...

Phase

Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery

PRIMARY OBJECTIVES: I. To collect and interrogate samples in patients with prostate cancer that were diagnosed with prostate cancer and are planned for radical prostatectomy at Mayo Clinic Arizona. SECONDARY OBJECTIVES: I. To describe the adverse event profile and tolerance of therapy for 60 days of treatment prior to surgery. ...

Phase